How and where to order Bimatoprost (Latisse, Lumigan, Careprost) ophthalmic solution 0.03% 3 ml online:
LATISSE (BIMATOPROST) OPHTHALMIC SOLUTION 0.03%: USE IN SPECIFIC POPULATIONS (see "References")
Pregnancy
Pregnancy Category C
Teratogenic effects: In embryo/fetal developmental studies in pregnant mice and rats, abortion was observed at oral doses of bimatoprost which achieved at least 33 or 97 times, respectively, the maximum intended human exposure (based on blood AUC levels after topical ophthalmic administration to the cornea or conjunctival sac).
At doses at least 41 times the maximum intended human exposure, the gestation length was reduced in the dams, the incidence of dead fetuses, late resorptions, peri- and postnatal pup mortality was increased, and pup body weights were reduced.
There are no adequate and well-controlled studies of bimatoprost ophthalmic solution 0.03% (Latisse) administration in pregnant women. Because animal reproductive studies are not always predictive of human response, Latisse should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers
It is not known whether Bimatoprost (Latisse) eye drops 0.03% is excreted in human milk, although in animal studies, bimatoprost has been shown to be excreted in breast milk. Because many drugs are excreted in human milk, caution should be exercised when Latisse is administered to a nursing woman.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
Geriatric Use
No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.
Recent posts:
Latisse prescribing information
|